Cathal Friel reverses Open Orphan into listed Venn Life Sciences - Raglan Capital

Home
About Us
Selected Transactions
Raglan IPO Projects
- Raglan Pharmaceutical & Life Science Projects
- Raglan Natural Resources
News
Contact us

Search

Cathal Friel reverses Open Orphan into listed Venn Life Sciences

Home
2019
Cathal Friel reverses Open Orphan into listed Venn Life Sciences

Recent News

Coronavirus: Canada suspends use of AstraZeneca shot for under-55s – as it happened
World’s first trial of deliberate coronavirus infection is approved
Scientists win approval to infect healthy volunteers with Covid for trial
Open Orphan gets final go-ahead for Covid-19 human trial
Covid-19: World’s first human challenge trials to start in UK
COVID-19: Volunteers to be exposed to virus in world-first study in UK

Cathal Friel reverses Open Orphan into listed Venn Life Sciences

10th May 2019

https://otp.investis.com/clients/uk/amryt_pharmaceuticals_dac1/rns/regulatory-story.aspx?cid=1375&newsid=1218097

Prev
Next

Join us for our newsletters

Raglan Capital
18 Fitzwilliam Place, Dublin 2.
T: +353 1 6440007
E: info@raglancapital.ie

Contact us
Careers
Privacy Policy
Cookie policy (EU)

Join us for our newsletters

Raglan Capital
18 Fitzwilliam Place, Dublin 2.
T: +353 1 6440007
E: info@raglancapital.ie

Contact us
Careers
Privacy Policy
Cookie policy (EU)

© 2021 Raglan Capital. All rights reserved

Privacy Preference Center

Privacy Preferences